ライフサイエンスコーパス: NSVT

1 NSVT (HR, 4.47 [95% CI, 1.87-10.72]; P=0.001) and VT ind

2 NSVT and ventricular ectopy were common early after TPVR

3 NSVT episodes were characterized by QRS morphology, dura

4 NSVT occurred frequently during the acute and convalesce

5 NSVT was not associated with LGE on CMR or VT inducibili

6 NSVT was significantly associated with ICD-treated VT/VF

7 NSVTs may serve as an initiator, and sustained VT induci

8 to 5,435) and increased with age (p < 0.01); NSVT was associated with greater left ventricular hypert

9 E (PVCs: 89% vs. 72%; couplets: 40% vs. 17%; NSVT: 28% vs. 4%; p < 0.0001 to 0.007).

10 atients without (group 1) and with (group 2) NSVT were balanced for variables: age, etiology of heart

11 range of SDB contributed 62 arrhythmias (76% NSVT).

12 Although NSVT that occurs within the first several hours of prese

13 time postdose (and the postdose timing of an NSVT event in a monkey).

14 OR, 6.20 [95 CI, 2.74-13.99]; P < .001), and NSVT (OR, 2.29 [95% CI, 1.10-4.51]; P = .03) at each fol

15 5), couplets (1.9 +/- 5 vs. 1.2 +/- 10), and NSVT runs (0.4 +/- 0.8 vs. 0.06 +/- 0.4) than non-DE pat

16 ure patients with ventricular arrhythmia and NSVT have a significantly increased risk of premature ca

17 e risk of paroxysmal atrial fibrillation and NSVT during sleep is markedly increased shortly after a

18 eened for paroxysmal atrial fibrillation and NSVT.

19 e than amiodarone in patients with NIDCM and NSVT is unknown.

20 d quality of life in patients with NIDCM and NSVT treated with amiodarone or an ICD are not statistic

21 3 beats; rate, >=120 bpm; lasting <30 s) and NSVT characteristics (coupling interval, duration, cycle

22 ection fraction < or =0.35, and asymptomatic NSVT were randomized to receive either amiodarone or an

23 h CAD and impaired LV function, asymptomatic NSVT identified in-hospital, compared with that identifi

24 Thus, the finding of asymptomatic NSVT on ambulatory ECG does not identify specific candid

25 ologic testing in patients with asymptomatic NSVT, CAD and LV dysfunction, eligible patients were enr

26 In trained athletes, NSVT is considered benign when suppressed by exercise.

27 for NSVT episodes, with associations between NSVT- and ICD-treated ventricular arrhythmias examined.

28 There was a time-varying interaction between NSVT and cardiovascular death such that NSVT was signifi

29 treated with reperfusion and beta-blockers, NSVT is not an independent predictor of long-term mortal

30 of a high-risk subgroup (ie, those with both NSVT and LGE on CMR).

31 , and most probably genetic channelopathies, NSVT carries prognostic significance, whereas its indepe

32 In patients with DCM, NSVT on Holter and VT inducibility during electrophysiol

33 For sudden death, NSVT on Holter ECG had negative and positive predictive

34 nitoring and ICD interrogation for detecting NSVT was poor (kappa=0.18).

35 exercise tests, in which 79 (3.7%) developed NSVT with exercise on at least 1 test.

36 Shortest RR interval during NSVT was also a univariate predictor of mortality.

37 djusting other variables, especially for EF, NSVT was not an independent predictor of all-cause morta

38 d syncope (1.9 to 14.9) (p = 0.002); 1.9 for NSVT (0.7 to 5.0) (p = 0.18) and 2.9 for LVWT (1.1 to 7.

39 terrogated and ambulatory ECGs monitored for NSVT episodes, with associations between NSVT- and ICD-t

40 yocardium were associated with more frequent NSVT on telemetry.

41 postimplant telemetry, 27 patients (50%) had NSVT, including 1 who had torsade de pointes, but most h

42 ; interquartile range, 8-23 g), 62 (54%) had NSVT on Holter, and sustained monomorphic VT was inducib

43 On discharge ERM, 37% of patients had NSVT, most with <5 episodes and only 13% with NSVT beyon

44 In acute myocardial infarction, in-hospital NSVT has an adverse prognostic significance when detecte

45 treated patients with in-hospital-identified NSVT and 11% and 21% for the out-of-hospital group (adju

46 y of ventricular tachyarrhythmias (including NSVT) on ambulatory Holter ECG.

47 d in 35% and 28% of the patients whose index NSVT occurred in-hospital and out-of-hospital, respectiv

48 ent for clinical variables, exercise-induced NSVT did not independently increase the risk of total mo

49 Exercise-induced NSVT occurred in nearly 4% of this asymptomatic adult co

50 and coronary risk factors, exercise-induced NSVT was not significantly associated with total mortali

51 On extended monitoring, NSVT was independently associated with ICD-treated ventr

52 iology study in 78% of SMVT patients, 48% of NSVT patients, and 4% of PVCs patients.

53 Detection of NSVT during the convalescent phase (n=428/1991; 21.5%) w

54 The median duration of NSVT was 3 beats (</=5 beats in 84%), and the median rat

55 ERM, 14% of patients had a single episode of NSVT and 1 had 5 episodes.

56 ss(i) (p < 0.001), and a higher frequency of NSVT (odds ratio 1.2; 95% confidence interval: 1.1 to 1.

57 variable demonstrated that the frequency of NSVT did not add significant information beyond the clin

58 ar arrhythmias, supporting the importance of NSVT in hypertrophic cardiomyopathy risk stratification.

59 The incidence of NSVT on follow-up ERM was similar to preimplant incidenc

60 fied time from presentation to occurrence of NSVT as the strongest predictor of mortality (P<0.0001).

61 the time from presentation to occurrence of NSVT increased, plateauing at approximately 24 hours wit

62 was time from presentation to occurrence of NSVT.

63 0.0001); DE was an independent predictor of NSVT (relative risk 7.3, 95% confidence interval 2.6 to

64 Holters were assessed for the presence of NSVT (>=3 beats; rate, >=120 bpm; lasting <30 s) and NSV

65 pital versus out-of-hospital presentation of NSVT.

66 ricular mechanics and a higher prevalence of NSVT.

67 The increased relative risk of NSVT was first significant when it occurred 13 hours fro

68 minute), shorter (</=7), or a single run of NSVT were not associated with ICD-treated ventricular ar

69 Repetitive runs of NSVT were also associated with ICD-treated VT/VF (adjust

70 ), longer (>7 beats), and repetitive runs of NSVT were more highly predictive of ICD-treated VT/VF.

71 Eighty-six (54%) patients had runs of NSVT, including 17 before implant on ambulatory monitori

72 We evaluated the prognostic significance of NSVT characteristics in the setting of acute MI.

73 etermined the prevalence and significance of NSVT in patients with PVCs and heart failure and on vaso

74 eart disease, the prognostic significance of NSVT is debatable.

75 However, the prognostic significance of NSVT when evaluated with other contemporary risk markers

76 Contrary to prevailing clinical opinion, NSVT that occurs in the setting of acute MI does have im

77 .93), couplets (8.5% vs. 8.4%; p = 0.99), or NSVT (8.3% vs. 8.5%; p = 0.35).

78 pisodes of paroxysmal atrial fibrillation or NSVT.

79 lar septum (n=5) were studied; 22% had prior NSVT and 24% were on prior rhythm medication.

80 es not have an associated adverse prognosis, NSVT that occurs beyond the first several hours after pr

81 during exercise, and especially at recovery, NSVT indicates increased cardiovascular mortality within

82 RR-NSVT during ICD interrogation is associated with appropr

83 RR-NSVT identified on routine ICD interrogation should be c

84 RR-NSVT was documented on ICD interrogation in 186 of 811 p

85 nown predictors of mortality in SCD-HeFT, RR-NSVT was independently associated with appropriate ICD s

86 In this study, the occurrence of RR-NSVT and its association with ICD shocks and mortality i

87 The occurrence of RR-NSVT and its association with ICD shocks and mortality i

88 The clinical implications of RR-NSVT identified during routine ICD interrogation are unc

89 The mean duration of RR-NSVT was 26.4 +/- 9.1 beats (7.5 +/- 2.6 s), with a mean

90 Polymorphic RR-NSVT accounted for 56% of episodes.

91 ate nonsustained ventricular tachycardia (RR-NSVT) during routine implantable cardioverter-defibrilla

92 The clinical evaluation of patients with RR-NSVT should include intensification of medical therapy,

93 with patients without RR-NSVT, those with RR-NSVT were less likely to be taking beta-blockers, statin

94 Compared with patients without RR-NSVT, those with RR-NSVT were less likely to be taking b

95 With a Cox regression model, specific NSVT characteristics were predictive of mortality.

96 on, coronary artery disease, and symptomatic NSVT are at highest risk of receiving appropriate ICD sh

97 In primary prevention, symptomatic NSVTs (HR, 8.0; 95% CI, 2.3-27.1; P=0.001) and subpulmon

98 T-segment elevation acute coronary syndrome, NSVT occurring beyond 48 h after admission indicates an

99 ncy of nonsustained ventricular tachycardia (NSVT) (36% vs. 11%; p = 0.01).

100 on and nonsustained ventricular tachycardia (NSVT) as well as a predilection for sudden cardiac death

101 Nonsustained ventricular tachycardia (NSVT) has been recorded in a wide range of conditions, f

102 Nonsustained ventricular tachycardia (NSVT) has significant prognostic implications in the set

103 tes of nonsustained ventricular tachycardia (NSVT) have been reported early after transcatheter pulmo

104 nduced nonsustained ventricular tachycardia (NSVT) in a large population of asymptomatic volunteers.

105 nce of nonsustained ventricular tachycardia (NSVT) in patients with hypertrophic cardiomyopathy is in

106 nce of nonsustained ventricular tachycardia (NSVT) in patients with premature ventricular contraction

107 Nonsustained ventricular tachycardia (NSVT) is common after acute coronary syndrome (ACS) and

108 which nonsustained ventricular tachycardia (NSVT) is discovered on the rate of inducibility of susta

109 aneous nonsustained ventricular tachycardia (NSVT) on Holter, VT inducibility during electrophysiolog

110 ncy of nonsustained ventricular tachycardia (NSVT) was the most powerful predictor and remained a sig

111 s, and nonsustained ventricular tachycardia (NSVT) were more common in patients with DE than those wi

112 (VT), nonsustained ventricular tachycardia (NSVT), and Lown's grade >=2 premature ventricular comple

113 titive nonsustained ventricular tachycardia (NSVT), or 3) premature ventricular contractions (PVCs).

114 ables: nonsustained ventricular tachycardia (NSVT), syncope, exercise blood pressure response (BPR),

115 ats of nonsustained ventricular tachycardia (NSVT).

116 %) had nonsustained ventricular tachycardia (NSVT).

117 M) and nonsustained ventricular tachycardia (NSVT).

118 omatic nonsustained ventricular tachycardia (NSVT; HR, 9.1; 95% CI, 2.8-29.2; P=0.001) were associate

119 e in the SMVT (10 of 15 patients [67%]) than NSVT or PVCs groups (p < 0.01).

120 ifically, the currently accepted notion that NSVT that occurs within 48 hours of acute MI has no prog

121 ween NSVT and cardiovascular death such that NSVT was significantly associated with increased risk wi

122 evidence is circumstantial, it suggests that NSVT is a potential JDTic toxicity in humans.

123 fibrillation occurred more frequently in the NSVT group (9% versus 0% in the control group; P<0.001),

124 the clinical variables with and without the NSVT variable demonstrated that the frequency of NSVT di

125 Pre-TPVR NSVT or rhythm medications, diagnosis other than tetralo

126 (61% vs. 11%; p < 0.001) and polymorphic VA (NSVT and VT: 19% vs. 2%; p = 0.002; premature ventricula

127 ilar patients, the clinical setting in which NSVT is discovered should be taken into account when for

128 The impact of the clinical setting in which NSVT is documented is unknown.

129 SVT, most with <5 episodes and only 13% with NSVT beyond 5 days post-discharge.

130 Eighteen of 86 patients (21%) with NSVT and 6 of 74 patients (8%) without NSVT experienced

131 x clinical arrhythmia of SMVT, 46 (36%) with NSVT, and 45 (35%) with PVCs.

132 ICD-treated VT/VF was associated with NSVT runs at a rate >200 beats per minute (adjusted haza

133 risk of cardiovascular death associated with NSVT was the greatest during the first 30 days after pre

134 tion that approximately 50% of patients with NSVT and approximately 5% of patients with PVCs have ind

135 s after presentation; however, patients with NSVT detected during the convalescent phase were also at

136 The management of patients with NSVT is aimed at treating the underlying heart disease.

137 Only in PM patients with NSVT or VT, the dominant morphology (right-bundle branch

138 abase was used to identify 112 patients with NSVT within 72 hours of acute MI.

139 tality rate, 1.1%) including 5 patients with NSVT.

140 with NSVT and 6 of 74 patients (8%) without NSVT experienced ICD-treated ventricular tachycardia (VT

141 Subjects with (vs. without) NSVT were older (67 +/- 12 years vs. 51 +/- 17 years, p